Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the ve most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).

Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis / Galli, Massimo; Antinori, Spinello; Atzeni, Fabiola; Meroni, Luca; Riva, Agostino; Scirè, Carlo; Adorni, Fulvio; Quartuccio, Luca; Sebastiani, Marco; Airò, Paolo; Bazzichi, Laura; Cristini, Francesco; Del Bono, Valerio; Manfredi, Andreina; Viapiana, Ombretta; De Rosa, Francesco; Favalli, Ennio; Petrelli, Enzo; Salvarani, Carlo; Govoni, Marcello; Corcione, Silvia; Scrivo, Rossana; Sarmati, Loredana; Lazzarin, Adriano; Grassi, Walter; Mastroianni, Claudio; Gaeta, Giovanni Battista; Ferraccioli, Gianfranco; Cutolo, Maurizio; De Vita, Salvatore; Lapadula, Giovanni; Matucci-Cerinic, Marco; Armignacco, Orlando; Sarzi-Puttini, Piercarlo. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - STAMPA. - 35:6(2017), pp. 1018-1028.

Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis

Scrivo, Rossana;Mastroianni, Claudio;
2017

Abstract

Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the ve most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).
2017
rheumatoid arthritis; pneumonia; fungal infection; recommendations
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis / Galli, Massimo; Antinori, Spinello; Atzeni, Fabiola; Meroni, Luca; Riva, Agostino; Scirè, Carlo; Adorni, Fulvio; Quartuccio, Luca; Sebastiani, Marco; Airò, Paolo; Bazzichi, Laura; Cristini, Francesco; Del Bono, Valerio; Manfredi, Andreina; Viapiana, Ombretta; De Rosa, Francesco; Favalli, Ennio; Petrelli, Enzo; Salvarani, Carlo; Govoni, Marcello; Corcione, Silvia; Scrivo, Rossana; Sarmati, Loredana; Lazzarin, Adriano; Grassi, Walter; Mastroianni, Claudio; Gaeta, Giovanni Battista; Ferraccioli, Gianfranco; Cutolo, Maurizio; De Vita, Salvatore; Lapadula, Giovanni; Matucci-Cerinic, Marco; Armignacco, Orlando; Sarzi-Puttini, Piercarlo. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - STAMPA. - 35:6(2017), pp. 1018-1028.
File allegati a questo prodotto
File Dimensione Formato  
Galli_Recommendations_2017.pdf

solo gestori archivio

Note: full-text
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 343.8 kB
Formato Adobe PDF
343.8 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1045223
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 14
social impact